Clinical Trial Update: Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety and tolerability trial of oral NS-018 in myelofibrosis patients completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• NS-018

Snippet

Sponsor: NS Pharma, Inc. | Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-03-09